Kardigan, Inc. 8K

Kardigan, Inc. announced second quarter 2026 financial results and business updates, including progress in three late-stage cardiovascular drug programs and a $460 million IPO that strengthened its cash position and extended its development runway.

On August 11, 2026, Kardigan, Inc. reported its financial results for the quarter ended June 30, 2026 and provided operational updates, highlighting advancement of its three late-stage cardiovascular programs, including initiation of enrollment in the Phase 3 portion of the KINSHIP-DCM trial for danicamtiv, continued progress in the KATALYST-AV Phase 2b trial for ataciguat and the KARDINAL-ASH Phase 2 trial for tonlamarsen, along with the completion in June 2026 of an initial public offering that generated approximately $460 million in gross proceeds, boosting its cash, cash equivalents and investments to $660.7 million and extending its cash runway through multiple upcoming clinical data readouts and planned Phase 3 trial initiations, despite a higher quarterly net loss driven by increased research and development spending.

Filing Facts

CIK

2123613

Ticker

KARD

Form

8K

Source Type

fda

Accession

0001193125-26-343395

Alert Tier

6